查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1586002

COVID-19 疫苗市場：按產品類型、最終用戶、患者類型 - 2025-2030 年全球預測

COVID-19 Vaccines Market by Product Type (Monovalent Vaccine, Multivalent Vaccine), End-User (Academic & Research Centers, Clinics, Hospitals), Patient Type - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年COVID-19疫苗市場規模為2,154.3億美元，預計2024年將達到2,371.2億美元，複合年成長率為10.55%，預計2030年將達4,348.3億美元。

COVID-19 疫苗市場研究範圍涵蓋與疫苗開發、分銷和採用相關的趨勢、市場動態和消費行為分析。這些疫苗的需求對於全球公共衛生至關重要，旨在減輕病毒的傳播並降低死亡率。 COVID-19 疫苗的最終用途涵蓋一般人群、醫療保健部門、政府和私營部門，包括跨人口群體的廣泛免疫、變異反應和潛在的加強劑量。市場洞察揭示了關鍵的成長要素，例如政府對疫苗創新的持續支持、公眾意識的提高以及 mRNA 技術的進步。但透過與國際衛生組織的合作和改善供應鏈物流，也有新的機會來擴大疫苗接種到服務不足地區的機會。可以透過利用技術進步和策略聯盟來加強分銷網路來利用這些機會。限制包括因錯誤訊息、監管障礙以及儲存和分發方面的後勤挑戰而導致的疫苗接種猶豫，尤其是在偏遠地區。此外，病毒的進化和新物種的出現正在改變疫苗的有效性，並帶來需要持續研究和適應的挑戰。為了克服這些挑戰，公司可以在疫苗儲存技術、供應鏈管理區塊鏈以及人工智慧主導的適應性疫苗配方研究等領域進行創新。該市場的特點是快速發展和激烈競爭，參與者不斷尋求增強其服務產品並擴大其區域影響力。製藥公司和高科技公司之間的合作可以促進疫苗開發和分配效率的顯著提高，從而提供一種全面的方法來對抗 COVID-19 及其不斷變化的威脅。

主要市場統計
基準年[2023] 2154.3億美元
預測年份 [2024] 2371.2億美元
預測年份 [2030] 4,348.3億美元
複合年成長率（%） 10.55%

市場動態：揭示快速發展的 COVID-19 疫苗市場的關鍵市場洞察

COVID-19 疫苗市場正在因供需的動態相互作用而發生轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 冠狀病毒迅速傳播導致大量死亡
    • 政府對 COVID-19 疫苗的支持和津貼
    • 加大疫苗研發舉措
  • 市場限制因素
    • 世界發展中地區的基礎設施、技能和技術支援有限
  • 市場機會
    • 生產和銷售 COVID-19 疫苗的合併活動增加
    • 加大疫苗投資
  • 市場挑戰
    • 與 COVID-19 疫苗相關的副作用

波特五力：駕馭 COVID-19 疫苗市場的策略工具

波特五力框架是了解 COVID-19 疫苗市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解 COVID-19 疫苗市場的外部影響

外部宏觀環境因素在塑造 COVID-19 疫苗市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解 COVID-19 疫苗市場的競爭格局

對 COVID-19 疫苗市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

COVID-19 疫苗市場中的 FPNV 定位矩陣供應商績效評估

FPNV 定位矩陣是評估 COVID-19 疫苗市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了 COVID-19 疫苗市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對 COVID-19 疫苗市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 冠狀病毒的迅速傳播導致許多人死亡
      • 政府對 COVID-19 疫苗的支持和津貼
      • 加強疫苗研發（R&D）舉措
    • 抑制因素
      • 全球發展中地區缺乏配套基礎建設、技能和技術
    • 機會
      • 擴大合併活動以製造和分銷 COVID-19 疫苗
      • 加大疫苗投資
    • 任務
      • 與 COVID-19 疫苗相關的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 COVID-19 疫苗市場：依產品類型

  • 單價疫苗
  • 多效價疫苗

第 7 章 COVID-19 疫苗市場：按最終用戶分類

  • 學術研究中心
  • 診所
  • 醫院
  • 疫苗接種中心

第 8 章按病患類型分類的 COVID-19 疫苗市場

  • 成人用
  • 小兒科
  • 老年人

第 9 章美洲 COVID-19 疫苗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區COVID-19疫苗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲的COVID-19疫苗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AIVITA Biomedical Inc.
  • AstraZeneca PLC
  • Baseimmune Ltd.
  • Bharat Biotech International Ltd.
  • Biological E. Ltd.
  • CanSino Biologics Inc.
  • Centivax Inc.
  • Codagenix Inc.
  • CureVac SE
  • Dr. Reddy's Laboratories Ltd.
  • Emergex Vaccines Holding Ltd.
  • Etherna Immunotherapies NV
  • Gennova Biopharmaceuticals Ltd.
  • GlaxoSmithKline PLC
  • HDT Bio, Inc.
  • Meissa Vaccines, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax Inc.
  • Osivax SAS
  • Pfizer Inc.
  • Providence Therapeutics Inc.
  • SANOFI
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Vaccitech PLC
  • Zydus Lifesciences Ltd.
Product Code: MRR-02026C4C976F

The COVID-19 Vaccines Market was valued at USD 215.43 billion in 2023, expected to reach USD 237.12 billion in 2024, and is projected to grow at a CAGR of 10.55%, to USD 434.83 billion by 2030.

The market research scope for COVID-19 vaccines encompasses the analysis of trends, market dynamics, and consumer behavior associated with vaccine development, distribution, and adoption. The necessity of these vaccines is imperative for global public health, aiming to mitigate the spread of the virus and reduce mortality rates, which directly influences economic recovery and societal well-being. The application of COVID-19 vaccines includes widespread immunization across demographic groups, addressing variants, and potential booster doses, with their end-use spanning the general public, healthcare sectors, and government and private entities. Market insights reveal key growth factors such as ongoing governmental support, a surge in public awareness, and advancements in mRNA technology that underpin vaccine innovation. However, emerging opportunities lie in expanding vaccine access to underserved regions through partnerships with international health organizations and improving supply chain logistics. These opportunities can be capitalized on by leveraging technological advancements and strategic alliances to bolster distribution networks. Limitations include vaccine hesitancy driven by misinformation, regulatory hurdles, and logistical challenges in storage and distribution, particularly in remote areas. Additionally, the virus's evolving nature and the emergence of new variants pose challenges that could alter vaccine efficacy and demand continuous research and adaptation. To navigate these challenges, businesses can innovate in areas such as vaccine storage technology, blockchain for supply chain management, and AI-driven research for adaptive vaccine formulations. The market is characterized by rapid advancements and intense competition, with players continuously seeking to enhance their offerings and expand their regional presence. Collaborations between pharmaceutical companies and tech firms could drive significant advancements in vaccine development and distribution efficiency, providing a comprehensive approach to combating COVID-19 and its evolving threats.

KEY MARKET STATISTICS
Base Year [2023] USD 215.43 billion
Estimated Year [2024] USD 237.12 billion
Forecast Year [2030] USD 434.83 billion
CAGR (%) 10.55%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving COVID-19 Vaccines Market

The COVID-19 Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rapid spread of coronavirus resulting in a large number of deaths
    • Government support and grants for COVID-19 vaccines
    • Increasing research and development (R&D) initiatives for vaccines
  • Market Restraints
    • Limited supportive infrastructure, skills, and technology in developing areas around the world
  • Market Opportunities
    • Growing amalgamation activities to manufacture and distribute the COVID-19 vaccines
    • Rising investments for vaccines
  • Market Challenges
    • Side effects associated with the COVID-19 vaccines

Porter's Five Forces: A Strategic Tool for Navigating the COVID-19 Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the COVID-19 Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the COVID-19 Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the COVID-19 Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the COVID-19 Vaccines Market

A detailed market share analysis in the COVID-19 Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the COVID-19 Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the COVID-19 Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the COVID-19 Vaccines Market

A strategic analysis of the COVID-19 Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the COVID-19 Vaccines Market, highlighting leading vendors and their innovative profiles. These include AIVITA Biomedical Inc., AstraZeneca PLC, Baseimmune Ltd., Bharat Biotech International Ltd., Biological E. Ltd., CanSino Biologics Inc., Centivax Inc., Codagenix Inc., CureVac SE, Dr. Reddy's Laboratories Ltd., Emergex Vaccines Holding Ltd., Etherna Immunotherapies NV, Gennova Biopharmaceuticals Ltd., GlaxoSmithKline PLC, HDT Bio, Inc., Meissa Vaccines, Inc., Merck & Co., Inc., Moderna, Inc., Novavax Inc., Osivax SAS, Pfizer Inc., Providence Therapeutics Inc., SANOFI, Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Vaccitech PLC, and Zydus Lifesciences Ltd..

Market Segmentation & Coverage

This research report categorizes the COVID-19 Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Monovalent Vaccine and Multivalent Vaccine.
  • Based on End-User, market is studied across Academic & Research Centers, Clinics, Hospitals, and Vaccination Centers.
  • Based on Patient Type, market is studied across Adult, Pediatric, and Senior Citizens.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rapid spread of coronavirus resulting in a large number of deaths
      • 5.1.1.2. Government support and grants for COVID-19 vaccines
      • 5.1.1.3. Increasing research and development (R&D) initiatives for vaccines
    • 5.1.2. Restraints
      • 5.1.2.1. Limited supportive infrastructure, skills, and technology in developing areas around the world
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing amalgamation activities to manufacture and distribute the COVID-19 vaccines
      • 5.1.3.2. Rising investments for vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with the COVID-19 vaccines
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. COVID-19 Vaccines Market, by Product Type

  • 6.1. Introduction
  • 6.2. Monovalent Vaccine
  • 6.3. Multivalent Vaccine

7. COVID-19 Vaccines Market, by End-User

  • 7.1. Introduction
  • 7.2. Academic & Research Centers
  • 7.3. Clinics
  • 7.4. Hospitals
  • 7.5. Vaccination Centers

8. COVID-19 Vaccines Market, by Patient Type

  • 8.1. Introduction
  • 8.2. Adult
  • 8.3. Pediatric
  • 8.4. Senior Citizens

9. Americas COVID-19 Vaccines Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific COVID-19 Vaccines Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa COVID-19 Vaccines Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AIVITA Biomedical Inc.
  • 2. AstraZeneca PLC
  • 3. Baseimmune Ltd.
  • 4. Bharat Biotech International Ltd.
  • 5. Biological E. Ltd.
  • 6. CanSino Biologics Inc.
  • 7. Centivax Inc.
  • 8. Codagenix Inc.
  • 9. CureVac SE
  • 10. Dr. Reddy's Laboratories Ltd.
  • 11. Emergex Vaccines Holding Ltd.
  • 12. Etherna Immunotherapies NV
  • 13. Gennova Biopharmaceuticals Ltd.
  • 14. GlaxoSmithKline PLC
  • 15. HDT Bio, Inc.
  • 16. Meissa Vaccines, Inc.
  • 17. Merck & Co., Inc.
  • 18. Moderna, Inc.
  • 19. Novavax Inc.
  • 20. Osivax SAS
  • 21. Pfizer Inc.
  • 22. Providence Therapeutics Inc.
  • 23. SANOFI
  • 24. Serum Institute of India Pvt. Ltd.
  • 25. Sinovac Biotech Ltd.
  • 26. Vaccitech PLC
  • 27. Zydus Lifesciences Ltd.

LIST OF FIGURES

  • FIGURE 1. COVID-19 VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. COVID-19 VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL COVID-19 VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL COVID-19 VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL COVID-19 VACCINES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL COVID-19 VACCINES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. COVID-19 VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. COVID-19 VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. COVID-19 VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL COVID-19 VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL COVID-19 VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. COVID-19 VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL COVID-19 VACCINES MARKET SIZE, BY MONOVALENT VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL COVID-19 VACCINES MARKET SIZE, BY MULTIVALENT VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL COVID-19 VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL COVID-19 VACCINES MARKET SIZE, BY SENIOR CITIZENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. COVID-19 VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. COVID-19 VACCINES MARKET, FPNV POSITIONING MATRIX, 2023